NFKB1 and cancer: In a previous study, platelet-derived TGFβ activated the Smad and NFκB pathways in cancer cells, resulting in EMT and enhanced metastasis in vivo; inhibition of NFκB signaling in cancer cells or ablation of TGFβ1 expression in platelets protected against lung metastasis in vivo [146,147].